Drug Safety

, Volume 36, Issue 10, pp 953–980 | Cite as

Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012

  • Sheena N. Ramasamy
  • Cameron S. Korb-Wells
  • Diluk R. W. Kannangara
  • Myles W. H. Smith
  • Nan Wang
  • Darren M. Roberts
  • Garry G. Graham
  • Kenneth M. Williams
  • Richard O. Day
Systematic Review

Abstract

Background

Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in tandem with the growing prevalence of gout globally. This exposes more patients to the risk of allopurinol hypersensitivity (AH), a rare adverse reaction characterised by a spectrum of cutaneous reactions and systemic manifestations. Severe forms of AH have been associated with high mortality. The pathophysiology underlying this reaction remains unknown, but several risk factors have been proposed.

Objective

The aim of this study was to review all published cases of AH documented in the literature in order to better understand the constellation of factors predisposing to this reaction, building on previous reviews by Lupton and Odom [163], Singer and Wallace [8]) and Arellano and Sacristan [9]).

Methods

A literature search was conducted in MEDLINE and EMBASE to identify relevant articles published between January 1950 and December 2012, with no language restrictions imposed. Articles that were included reported either allopurinol-induced cutaneous manifestations alone or satisfied the diagnostic criteria for AH as defined by Singer and Wallace.

Results

Nine hundred and one patients (overall AH cohort) were identified from 320 publications. Of these patients, 802 satisfied the Singer and Wallace criteria (‘Singer and Wallace’ cohort) while 99 patients had only mild cutaneous manifestations (‘non-Singer and Wallace’ cohort). Data were often incomplete; hence the results reported reflect the fractions of the subsets of the cohort where the data in question were available. In the overall AH cohort, 58 % (416/722) were male. The majority (73 %; 430/590) of patients were Asian. Renal impairment (48 %; 182/376) and hypertension (42 %; 160/376) were the most common chronic conditions; accordingly, diuretics (45 %; 114/252) and antihypertensives (39 %; 99/252) were the most prevalent concomitant medications. Allopurinol was prescribed for approved indications (chronic gout and chemoprophylaxis) in only 40 % (186/464) of patients. The median allopurinol dose was 300 mg/day (range 10–1,000 mg/day) and was taken by 50 % (168/338). There was no significant association between a higher dose (>300 mg/day) and an increased risk of severe cutaneous manifestations [odds ratio (OR) 1.76; 95 % CI 0.73–4.22; p = 0.23]. Approximately 90 % (489/538) of patients developed AH within 60 days of initiating allopurinol therapy. Serum oxypurinol (the active metabolite of allopurinol) concentration was only recorded in six patients, four of whom had levels within the putative therapeutic range of 30–100 μmol/L. The HLA-B*5801 allele was present in 99 % (166/167) of patients tested, with the majority (147/166) being of Asian ancestry. The all-cause mortality rate was 14 % (109/788) with 94 AH-related deaths, all of which occurred in the cohort meeting the Singer and Wallace criteria.

Limitations

The publications included in this review utilized different laboratory reference ranges to classify the non-cutaneous manifestations of AH; this may have introduced some variation in the cases identified as AH. A majority of the articles included in this analysis consisted of case reports and series—publication types that are not recognized as best-quality evidence; this thus limited the conclusions we could draw about the many risk factors we were interested in evaluating.

Conclusions

Risk factors associated with AH, such as concomitant diuretic use, pre-existing renal impairment and recent initiation of allopurinol, were commonly present in AH patients; however, their role in the mechanism of AH remains to be established. A clear risk factor was the HLA-B*5801 status; this was especially relevant in Asian populations where there is a higher carriage rate of the allele. High allopurinol dose, previously suggested to be a risk factor, was not confirmed as such. The paucity of well-documented case reports and studies of AH render it difficult to draw more concrete conclusions or construct a meticulous profile of patients at risk of AH. Future case reports of AH need to be better documented to contribute to understanding the risks for, and mechanisms of, AH.

References

  1. 1.
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64:229–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Bradlow A. Adverse reactions profile: allopurinol. Prescr J. 1997;37:29–33.Google Scholar
  3. 3.
    Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114.PubMedCrossRefGoogle Scholar
  4. 4.
    Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623–44.PubMedCrossRefGoogle Scholar
  5. 5.
    McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40:245–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. BMJ. 1985;290:1969–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72:1361–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337–43.PubMedGoogle Scholar
  10. 10.
    Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20:391–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529–36.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993–96). J Rheumatol. 2001;28:1640–6.PubMedGoogle Scholar
  15. 15.
    Minaur N, Sawyers S, Parker J, et al. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004;31:965–72.PubMedGoogle Scholar
  16. 16.
    Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10:R17.PubMedCrossRefGoogle Scholar
  17. 17.
    Anagnostopoulos I, Zinzaras E, Alexiou I, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98.PubMedCrossRefGoogle Scholar
  18. 18.
    Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13:R39.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012;42:997–1007.Google Scholar
  21. 21.
    Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901–9.CrossRefGoogle Scholar
  22. 22.
    Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12:1741–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Chung Y, Lu CY, Graham GG, et al. Utilization of allopurinol in the Australian community. Intern Med J. 2008;38:388–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Klinenberg JR. The effectiveness of allopurinol in the treatment of gout. Arthritis Rheum. 1965;8:891–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Scott JT, Hall AP, Grahame R. Allopurinol in treatment of gout. Br Med J. 1966;2:321–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Blechman WJ, Rosenberg DG, Hilf P. Use of allopurinol in gout, hyperuricemia and uric acid lithiasis. South Med J. 1967;60:215–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Muggia FM, Ball TJ Jr, Ultmann JE. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967;120:12–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Wilson JD, Simmonds HA, North JD. Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis. 1967;26:136–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Manahan LA, Portes JC. Allopurinol in the treatment of gout. Acta Medica Philipp. 1968;4:189–97.Google Scholar
  33. 33.
    Kantor GL. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA. 1970;212:478–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Bailey RR, Neale TJ, Lynn KL. Allopurinol-associated arteritis. Lancet. 1976;2:907.PubMedCrossRefGoogle Scholar
  35. 35.
    Espiritu CR, Alalu J, Glueckauf LG, et al. Allopurinol-induced granulomatous hepatitis. Am J Dig Dis. 1976;21:804–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Butler RC, Shah SM, Grunow WA, et al. Massive hepatic necrosis in a patient receiving allopurinol. JAMA. 1977;237:473–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Gelbart DR, Weinstein AB, Fajardo LF. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86:196–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Medline A, Cohen LB, Tobe BA, et al. Liver granulomas and allopurinol. Br Med J. 1978;1:1320–1.PubMedCrossRefGoogle Scholar
  39. 39.
    Burkle WS. Allopurinol hypersensitivity. Drug Intell Clin Pharm. 1979;13:218–23.Google Scholar
  40. 40.
    Fam AG, Paton TW, Chaiton A. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions. Can Med Assoc J. 1980;123:128–9.PubMedGoogle Scholar
  41. 41.
    Hamilton DV, Shah PJR, Pryor JS, et al. Acute vasculitis and exacerbation of renal failure secondary to allopurinol hypersensitivity. Dial Transpl. 1980;9:78.Google Scholar
  42. 42.
    Link F, Mueller-Fassbender H. Drug-induced lupus erythematodes (DILE): minor tranquillizers and allopurinol as general inducers of the DILE syndrome? [German] Medikamentos Induzierter Lupus Erythematodes. Minor-Tranquilizers Und Allopurinol Als ‘General Inducers’ Des Di-Le Syndroms. Munchener Medizinische Wochenschrift. 1980;122:1099–100.PubMedGoogle Scholar
  43. 43.
    Daul AE, Graben N, Anlauf M, et al. Generalized vasculitis as potentially fatal side effect of allopurinol. [German] Generalisierte Vaskulitis Als Lebensbedrohliche Nebenwirkung Von Allopurinol. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin. 1981;87:1235–8.Google Scholar
  44. 44.
    Gotz VP, Salem R. Bullae associated with allopurinol. Drug Intell Clin Pharm. 1981;15:490–1.Google Scholar
  45. 45.
    Lee EJ, Kueh YK. Allopurinol-induced skin reactions and agranulocytosis. Singap Med J. 1982;23:178–80.Google Scholar
  46. 46.
    Ramond MJ, Nouel O, Degott C, et al. Allopurinol-induced hepatitis: report of a case and review of the literature (author’s transl). Gastroenterol Clin Biol. 1982;6:138–42.PubMedGoogle Scholar
  47. 47.
    Bruguera M, Libre J, Aubia J, et al. Allopurinol-induced cholestasis. [Spanish] Colestasis Por Alopurinol. Gastroenterologia y Hepatologia. 1983;6:253–5.Google Scholar
  48. 48.
    Halebian P, Corder V, Herndon D, et al. A burn center experience with toxic epidermal necrolysis. J Burn Care Res. 1983;4:176–83.CrossRefGoogle Scholar
  49. 49.
    Dan M, Jedwab M, Peled M, et al. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol. 1984;23:142–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Fong PH, Ratnagopal P, Wong KL. Drug induced toxic epidermal necrolysis. Singap Med J. 1984;25:184–6.Google Scholar
  51. 51.
    Ebel V, Baumann R, Czechanowski B. Five cases of drug-induced Lyell’s syndrome. [German] Funf Falle Mit Medikamenten-Induziertem Lyell-Syndrom. Innere Medizin. 1985;12:280–4.Google Scholar
  52. 52.
    Renwick IG. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J. 1985;291:485 (Clinical Research Ed).CrossRefGoogle Scholar
  53. 53.
    Zakraoui L, Daly L, Hamza M. Lyell’s syndrome happened to a patient treated by allopurinol. [French] Syndrome De Lyell Survenant Chez Une Patiente Traitee Par L’allopurinol. Tunisie Medicale. 1985;63:167–70.PubMedGoogle Scholar
  54. 54.
    Durst UN, Muller E, Pfister T. Toxic epidermal necrolysis (Lyell’s syndrome). [German] Toxische Epidermale Nekrolyse (Lyell-Syndrom). Schweiz Med Wochenschr. 1986;116:713–20.PubMedGoogle Scholar
  55. 55.
    Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol. 1986;63:525–34.PubMedCrossRefGoogle Scholar
  56. 56.
    Kumar L. Allopurinol induced toxic epidermal necrolysis. Indian J Dermatol. 1986;31:53–4.PubMedGoogle Scholar
  57. 57.
    Rayle RT. 5 nursing lessons from a patient with T.E.N. Am J Nurs. 1986;86:300–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Balacco-Gabrieli C, Palmisano C, Lorusso V, et al. Lyell’s syndrome caused by allopurinol. Clinical case. Ophtalmologie. 1988;2:123–6.PubMedGoogle Scholar
  59. 59.
    Sauve C, Pinquier JL, Boissonnad A, et al. Systemic allopurinol toxicity. Eur J Intern Med. 1992;3:78–81.Google Scholar
  60. 60.
    Yu RC, Chu TC. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1993;128:95–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Carsuzaa F, Pierre C, Morand JJ, et al. Allopurinol hypersensitivity syndrome: Erythema annulare centrifugum. [French] Syndrome D’hypersensibilite a L’allopurinol a Type D’erytheme Annulaire Centrifuge. Nouvelles Dermatologiques. 1994;13:670–1.Google Scholar
  62. 62.
    Ioannides D, Vakali G, Chrysomallis F, et al. Toxic epidermal necrolysis: a study of 22 cases. J Eur Acad Dermatol Venereol. 1994;3:266–75.CrossRefGoogle Scholar
  63. 63.
    Richter G, Blasum C. Allopurinol hypersensitivity syndrome. [German] Allopurinol-Hypersensitivitatssyndrom. Aktuelle Dermatologie. 1994;20:217–9.Google Scholar
  64. 64.
    Bang HD, Chung JH, Cho KH, et al. Three cases of allopurinol hypersensitivity syndrome. Korean J Dermatol. 1995;33:130–4.Google Scholar
  65. 65.
    Baroni T, Bocor M. Erythemato-maculo-papular eruption induced by allopurinol. [Italian] Eruzione Eritemato-Maculo-Papulosa Da Allopurinolo. Giornale Italiano di Dermatologia e Venereologia. 1995;130:45–7.Google Scholar
  66. 66.
    Domingues-Costa A, Marques P, Vaz-Da-Silva M. The allopurinol hypersensitivity syndrome: A case report. [Portuguese] Sindrome De Hipersensibilidade Ao Alopurinol. A Proposito De Um Caso Clinico. Arquivos de Medicina. 1996;10:48–54.Google Scholar
  67. 67.
    Kruppa A, Smola H, Scharffetter-Kochanek K, et al. Allopurinol-induced allergic vasculitis. [German] Vasculitis allergica auf Allopurinol. H+G Zeitschrift fur Hautkrankheiten. 1996;71:868–9.Google Scholar
  68. 68.
    Gimbel Moral LF, De Miguel Sanchez C, Mugarza Hernandez MD, et al. Erupcion Fija Medicamentosa Causada Por Alopurinol. Medicina Clinica. 1996;106:119.Google Scholar
  69. 69.
    Sabaris Ma CF, Duran EP, Garcia-Patos PE, et al. Generalized acute exanthematic pustulosis due to allopurinol. [Spanish] Pustulosis exantematica aguda generalizada por alopurinol. Actas Dermo-Sifiliograficas. 1996;87:471–4.Google Scholar
  70. 70.
    Akriditis NK, Sakkas LI. Leukocytoclastic vasculitis. Consultant. 1997;37:1414.Google Scholar
  71. 71.
    Higuchi S, Yamamoto M. A case of Stevens–Johnson syndrome associated with allopurinol hypersensitivity [Japanese]. Acta Dermatologica Kyoto. 1997;92:367–73.Google Scholar
  72. 72.
    Schnyder B, Zanni MP, Pichler WJ. Drug-induced hypersensitivity syndrome. A review and presentation of 2 personal cases. Schweiz Med Wochenschr. 1997;127:355–9.PubMedGoogle Scholar
  73. 73.
    Calvino JA, Burgos RR, Mardaras J, et al. Hypersensitivity syndrome and granulomatous interstitial nephritis associated with allopurinol. [Spanish] Sindrome de hipersensibilidad y nefritis intersticial granulomatosa aguda asociada al alopurinol. Nefrologia. 1998;18:238–42.Google Scholar
  74. 74.
    Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026–32.PubMedCrossRefGoogle Scholar
  75. 75.
    Kluger E. Fatal outcome in allopurinol hypersensitivity syndrome. Ugeskr Laeger. 1998;160:1179–80.PubMedGoogle Scholar
  76. 76.
    Torralba FJ, Sanchez-Carbayo M, Gil MT, et al. Allopurinol hypersensitivity. [Spanish] Hipersensibilidad a alopurinol. Nefrologia. 1998;18:81–5.Google Scholar
  77. 77.
    Voets AJ, Joesoef KS. Allopurinol toxicity after coronary artery bypass grafting. Clin Intensive Care. 1998;9:88–9.Google Scholar
  78. 78.
    Wooten MD, Lipsmeyer E. Gout accompanying rheumatoid arthritis: a comparison of affected women and men. J Clin Rheumatol. 1998;4:220–4.PubMedGoogle Scholar
  79. 79.
    Hari Y, Urwyler A, Hurni M, et al. Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol. 1999;120:225–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Buna D. Allopurinol hypersensitivity syndrome: a case report and review. Can J Hosp Pharm. 2000;53:36–9.Google Scholar
  81. 81.
    Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–3.PubMedCrossRefGoogle Scholar
  82. 82.
    Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001;31:1398–408.PubMedCrossRefGoogle Scholar
  83. 83.
    Ortega JD, Trindade C, Llamazares A, et al. Hypersensitivity to allopurinol. Efficacy of a desensitization procedure in three cases. [Spanish] Hipersensibilidad al alopurinol. Eficacia de un protocolo de desensibilizacion en tres casos. Anales de Medicina Interna. 2001;18:27–8.Google Scholar
  84. 84.
    Hoffman LA. My gout and allopurinol desensitization. J Clin Rheumatol. 2002;8:354–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Joshi A, Verma A, Gulati A, et al. Toxic epidermal necrolysis in a patient of chronic myeloid leukemia treated successfully with high dose steroids. J Inter Med India. 2002;5:40–2.Google Scholar
  86. 86.
    Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Derm Venereol. 2002;82:316–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Nishimura S, Shinoda T, Suzuki Y, et al. Drug-induced MPO-ANCA-positive necrotizing crescentic glomerulonephritis preceded by granulomatous hepatitis. Clin Exp Nephrol. 2002;6:118–20.CrossRefGoogle Scholar
  88. 88.
    Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:155–61.PubMedCrossRefGoogle Scholar
  89. 89.
    Sommers LM, Schoene RB. Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus. Arch Intern Med. 2002;162:1190–2.PubMedCrossRefGoogle Scholar
  90. 90.
    Chubar Y, Bennett M. Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol. 2003;122:768–70.PubMedCrossRefGoogle Scholar
  91. 91.
    Hirashima N, Misago N, Nakafusa J, et al. Two cases of drug-induced hypersensitivity syndrome [Japanese]. Nishinihon J Dermatol. 2003;65:365–9.CrossRefGoogle Scholar
  92. 92.
    Kim BJ, Kim MN, Ro BI, et al. A case of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2003;41:251–4.Google Scholar
  93. 93.
    Nitti F, Fumagalli M, Incorvaia C. Rush desensitization to allopurynol. Allergy. 2003;58:690.PubMedCrossRefGoogle Scholar
  94. 94.
    Koizumi H, Tsunoda T, Ito O, et al. A case of drug-induced hypersensitivity syndrome (DIHS) caused by allopurinol [Japanese]. Nishinihon J Dermatol. 2004;66:37–9.CrossRefGoogle Scholar
  95. 95.
    Takayasu S, Nasu N, Hoshino T, et al. Drug eruption associated with allopurinol and vancomycin in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). A case report [Japanese]. Nishinihon J Dermatol. 2004;66:479–81.CrossRefGoogle Scholar
  96. 96.
    Cho WI, Yoon YH, Kim MN, et al. Two cases of allopurinol hypersensitivity syndrome due to use of allopurinol for the patient with asymptomatic hyperuricemia [Korean]. Korean J Dermatol. 2005;43:961–4.Google Scholar
  97. 97.
    Kim JW, Kim JS, Kim KJ. A clinical observation of drug hypersensitivity syndrome and serologic and molecular genetic analyses of human herpesvirus-6 reactivation [Korean]. Korean J Dermatol. 2005;43:143–50.Google Scholar
  98. 98.
    Kwon KS, Kim BS, Jang BS, et al. Clinical study of drug rash with eosinophilia and systemic symptoms (DRESS) on drug eruption patients over the last 10 years (1995–2004) [Korean]. Korean J Dermatol. 2005;43:1164–9.Google Scholar
  99. 99.
    Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens–Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 2005;35:188–90.PubMedCrossRefGoogle Scholar
  100. 100.
    Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504–10.PubMedCrossRefGoogle Scholar
  101. 101.
    Mantha S, Jacobs MI, Savage DG. Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:5841–3.PubMedCrossRefGoogle Scholar
  102. 102.
    Marie E, Fournier C, Bautin N, et al. Ultra-rush desensitization to allopurinol. [French] Accoutumance ultrarapide a l’allopurinol. Revue Francaise d’Allergologie et d’Immunologie Clinique. 2005;45:498–500.CrossRefGoogle Scholar
  103. 103.
    Park MW, Kim SS, Lee JJ. Two cases of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2005;43:114–7.Google Scholar
  104. 104.
    Song HJ, Kim CO, Lee KS. Two cases of allopurinol hypersensitivity syndrome in patients receiving thiazide therapy due to hypertension [Korean]. Korean J Dermatol. 2005;43:1426–9.Google Scholar
  105. 105.
    Stingeni L, Zeppa L, Lisi P. Allopurinol induced DRESS syndrome: Clinical and pathogenetic remarks. [Italian] Sindrome da ipersensibilita ad allopurinolo: Considerazioni clinicopatogenetiche. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale. 2005;59:115–7.Google Scholar
  106. 106.
    Wang D, Xhu XJ. Gouty patient hypersensitive to allopurinol: an intractable case. J Dermatol. 2005;32:64–5.PubMedGoogle Scholar
  107. 107.
    Das R. Allopurinol-associated angitis. J Pharm Pract Res. 2006;36:77.Google Scholar
  108. 108.
    Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155:344–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Torres MJ, Mayorga C, Fernandez TD, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol. 2006;19:119–30.PubMedGoogle Scholar
  110. 110.
    Vahid B, Wildemore B, Lin T, et al. What caused diffuse alveolar hemorrhage in a patient with gout? J Respir Dis. 2006;27:441–3.CrossRefGoogle Scholar
  111. 111.
    Wung DC, Cheng MF, Huang JJ, et al. Corticosteroid therapy in allopurinol hypersensitivity syndrome: a case report [Chinese]. J Intern Med Taiwan. 2006;17:133–40.Google Scholar
  112. 112.
    Calogiuri G, Muratore L, Congedo M, et al. Alternative treatments in allopurinol hypersensitivity syndrome: a case report. [Italian] Alternative terapeutiche nella sindrome da ipersensibilita all’allopurinolo: Descrizione di un caso clinico. Italian. J Allergy Clin Immunol. 2007;17:66–70.Google Scholar
  113. 113.
    Cornejo-Garcia JA, Fernandez TD, Torres MJ, et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy. 2007;62:1429–38.PubMedCrossRefGoogle Scholar
  114. 114.
    Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven–Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci. 2007;11:119–27.PubMedGoogle Scholar
  115. 115.
    Nishio D, Izu K, Kabashima K, et al. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007;48:25–33.PubMedCrossRefGoogle Scholar
  116. 116.
    Paquet P, Jacob E, Quatresooz P, et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns. 2007;33:100–4.PubMedCrossRefGoogle Scholar
  117. 117.
    Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419–25.PubMedCrossRefGoogle Scholar
  118. 118.
    Fortunati M, Dewulf V, Jouret F, et al. “DRESS syndrome”or systemic allopurinol hypersensitivity syndrome. [French] «DRESS syndrome» ou syndrome d’hypersensibilite systemique a l’allopurinol. Louvain Med. 2008;127:376–9.Google Scholar
  119. 119.
    Roche Gamon E, Carazo JLS, Argente CL, et al. Delayed allopurinol hypersensitivity syndrome. [Spanish] Sindrome de hipersensibilidad retardada a alopurinol. Piel. 2008;23:166–8.CrossRefGoogle Scholar
  120. 120.
    Koike M, Kanno Y, Tomori K, et al. Viruses may trigger allopurinol hypersensitivity syndrome. NDT Plus. 2008;1:273–4.CrossRefGoogle Scholar
  121. 121.
    Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med. 2008;121:e3–4.PubMedCrossRefGoogle Scholar
  122. 122.
    Tohyama M, Shirakata Y, Sayama K, et al. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome. Br J Dermatol. 2008;159:981–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol. 2009;145:1030–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61:1268–70.PubMedCrossRefGoogle Scholar
  125. 125.
    Kemen C, Lemke J, Hoeger PH, et al. Human leukocyte antigen-related risk factors for toxic epidermal necrosis. Pediatr Infect Dis J. 2009;28:552.PubMedCrossRefGoogle Scholar
  126. 126.
    Tamzaourte M, Errabih I, Krami H, et al. Acute cytolytic hepatitis induced by allopurinol in a patient treated for hepatitis C. [French] Hepatite aigue cytolytique induite par l’allopurinol chez un patient traite pour hepatite virale C. Journal Africain d’Hepato-Gastroenterologie. 2009;3:160–2.CrossRefGoogle Scholar
  127. 127.
    Ang CC, Wang YS, Yoosuff EL, et al. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63:219–27.PubMedCrossRefGoogle Scholar
  128. 128.
    Bellon T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol. 2010;162:1014–22.PubMedCrossRefGoogle Scholar
  129. 129.
    Bennett S, Mitsides N, Dhaygude A, et al. A pilot in distress. NDT Plus. 2010;3:84–8.CrossRefGoogle Scholar
  130. 130.
    Chaabane A, Aouam K, Fredj NB, et al. DRESS syndrome: 11 Case reports and a literature review. [French] DRESS syndrome: Etude de 11 cas et revue de la litterature. Therapie. 2010;65:543–50.PubMedCrossRefGoogle Scholar
  131. 131.
    Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146:1373–9.PubMedCrossRefGoogle Scholar
  132. 132.
    Cooksley T, Iqbal J, Robertson C, et al. DRESS syndrome caused by allopurinol. Acute Med. 2010;9:122–3.PubMedGoogle Scholar
  133. 133.
    Elia F, Apra F. A potentially fatal cause of rash. Int J Emerg Med. 2010;3:491–2.PubMedCrossRefGoogle Scholar
  134. 134.
    Flores SM, Hidalgo LG, Topete RO. Erithrodermia as presentation of DRESS syndrome associated with allopurinol. A report of a case. [Spanish] Eritrodermia como presentacion del sindrome DRESS asociado con alopurinol. Comunicacion de un caso. Dermatologia Revista Mexicana. 2010;54:104–7.Google Scholar
  135. 135.
    Ben Fredj N, Aouam K, Chaabane A, et al. Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin Pharmacol. 2010;70:273–6.PubMedCrossRefGoogle Scholar
  136. 136.
    Lee T, Bae YJ, Park SK, et al. Severe pneumonia caused by combined infection with Pneumocystis jiroveci, parainfluenza virus type 3, cytomegalovirus, and Aspergillus fumigatus in a patient with Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2010;90:625–9.PubMedCrossRefGoogle Scholar
  137. 137.
    Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur J Dermatol. 2010;20:68–73.PubMedGoogle Scholar
  138. 138.
    Peppercorn AF, Miller MB, Fitzgerald D, et al. High-level human herpesvirus-6 viremia associated with onset of Stevens–Johnson syndrome: report of two cases. J Burn Care Res. 2010;31:365–8.PubMedCrossRefGoogle Scholar
  139. 139.
    Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: a case report and literature review. BMJ Case Rep. 2011. doi:10.1136/bcr.02.2011.3898.
  140. 140.
    Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38:1957–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transpl. 2011;26:3567–72.CrossRefGoogle Scholar
  142. 142.
    Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21:385–91.PubMedGoogle Scholar
  143. 143.
    Ranu H, Jiang J, Ming PS. A case series of allopurinol-induced toxic epidermal necrolysis. Indian J Dermatol. 2011;56:74–6.PubMedCrossRefGoogle Scholar
  144. 144.
    Teo WL, Pang SM, Koh HY. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol. 2011;30:243–4.PubMedCrossRefGoogle Scholar
  145. 145.
    Aach R, Kissane J. Hypertension, hyperuricemia and iatrogenic disease. Am J Med. 1970;49:242–9.CrossRefGoogle Scholar
  146. 146.
    Jarzobski J, Ferry J, Wombolt D, et al. Vasculitis with allopurinol therapy. Am Heart J. 1970;79:116–21.PubMedCrossRefGoogle Scholar
  147. 147.
    Mills RM Jr. Severe hypersensitivity reactions associated with allopurinol. JAMA. 1971;216:799–802.PubMedCrossRefGoogle Scholar
  148. 148.
    Simmons F, Feldman B, Gerety D. Granulomatous hepatitis in a patient receiving allopurinol. Gastroenterology. 1972;62:101–4.PubMedGoogle Scholar
  149. 149.
    Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974;134:553–8.PubMedCrossRefGoogle Scholar
  150. 150.
    Ellman MH, Fretzin DF, Olson W. Toxic epidermal necrolysis associated with allopurinol administration. Arch Dermatol. 1975;111:986–90.PubMedCrossRefGoogle Scholar
  151. 151.
    Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity vasculitis and liver damage. West J Med. 1977;126:143–7.PubMedGoogle Scholar
  152. 152.
    Lockard O Jr, Harmon C, Nolph K, et al. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med. 1976;85:333–5.PubMedCrossRefGoogle Scholar
  153. 153.
    McMenamin RA, Davies LM, Craswell PW. Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust N Z J Med. 1976;6:583–7.PubMedCrossRefGoogle Scholar
  154. 154.
    Utsinger PD, Young WJ. Allopurinol hypersensitivity. Granular deposition of IgM at the dermal-epidermal junction. Am J Med. 1976;61:287–94.PubMedCrossRefGoogle Scholar
  155. 155.
    Chan HL, Ku G, Khoo OT. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med. 1977;7:518–22.PubMedCrossRefGoogle Scholar
  156. 156.
    Devulder B, Plouvier B, Francois M, et al. Zeek’s angiitis during combination treatment with allopurinol and a thiazide diuretic. Lille Med. 1977;22:798–800.PubMedGoogle Scholar
  157. 157.
    Calin A. Allopurinol toxicity masquerading as malignancy. JAMA. 1978;239:497.PubMedCrossRefGoogle Scholar
  158. 158.
    Korting HC, Lesch R. Acute cholangitis after allopurinol treatment. Lancet. 1978;1:275–6.PubMedCrossRefGoogle Scholar
  159. 159.
    Lindsey SW, Evans EF. Allpurinol hypersensitivity syndrome: effects and treatment. Va Med. 1978;105:297–9.PubMedGoogle Scholar
  160. 160.
    Male PJ, Schaer B, Posternak F. Hypersensitivity reaction to allopurinol. Schweiz Med Wochenschr. 1978;108:681–3.PubMedGoogle Scholar
  161. 161.
    Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med. 1978;138:997–8.PubMedCrossRefGoogle Scholar
  162. 162.
    Haughey DB, Lanse S, Imhoff T, et al. Allopurinol sensitivity: report of two cases. Am J Hosp Pharm. 1979;36:1377–80.PubMedGoogle Scholar
  163. 163.
    Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365–74.PubMedCrossRefGoogle Scholar
  164. 164.
    McKendrick MW, Geddes AM. Allopurinol hypersensitivity. Br Med J. 1979;1:988.PubMedCrossRefGoogle Scholar
  165. 165.
    Phanichphant S, Boonpucknavig V. Allopurinol associated hypersensitivity. J Med Assoc Thai. 1980;63:155–63.PubMedGoogle Scholar
  166. 166.
    Al-Kawas FH, Seeff LB, Berendson RA, et al. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med. 1981;95:588–90.PubMedCrossRefGoogle Scholar
  167. 167.
    Grussendorf M, Andrassy K, Waldherr R, et al. Systemic hypersensitivity to allopurinol with acute interstitial nephritis. Am J Nephrol. 1981;1:105–9.PubMedCrossRefGoogle Scholar
  168. 168.
    Irino S, Sanada H, Maesako N, et al. A case of angio-immunoblastic lymphadenopathy with dysproteinemia related to allopurinol. Acta Med Okayama. 1981;35:263–72.PubMedGoogle Scholar
  169. 169.
    Earll JM, Saavedra M. Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983;28:147–8.PubMedGoogle Scholar
  170. 170.
    Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm. 1985;19:431–3.PubMedGoogle Scholar
  171. 171.
    Stein CM. Allopurinol hypersensitivity. A case report. S Afr Med J. 1985;67:935–6.PubMedGoogle Scholar
  172. 172.
    Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum. 1985;28:707–9.PubMedCrossRefGoogle Scholar
  173. 173.
    Guerin C, Genin C, Toulon J, et al. Allopurinol toxicity. Apropos of 1 case. Nephrologie. 1986;7:47–9.PubMedGoogle Scholar
  174. 174.
    Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ. 1986;135:1278–81.PubMedGoogle Scholar
  175. 175.
    Magner P, Sweet J, Bear RA. Granulomatous interstitial nephritis associated with allopurinol therapy. CMAJ. 1986;135:496–7.PubMedGoogle Scholar
  176. 176.
    Mousson C, Justrabo E, Tanter Y, et al. Acute granulomatous interstitial nephritis and hepatitis caused by drugs. Possible role of an allopurinol-furosemide combination. Nephrologie. 1986;7:199–203.PubMedGoogle Scholar
  177. 177.
    Pan HY, Glazener FS. The mackerel was in fact a red herring. Drug Intell Clin Pharm. 1986;20:687–9.PubMedGoogle Scholar
  178. 178.
    Schillinger F, Montagnac R, Milcent T. A new case of severe allopurinol toxicity. Nephrologie. 1986;7:214.PubMedGoogle Scholar
  179. 179.
    Vanderstigel M, Zafrani ES, Lejonc JL, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology. 1986;90:188–90.PubMedGoogle Scholar
  180. 180.
    Arbeteta J, Ledo L, Teruel JL, et al. Severe adverse reaction to allopurinol. Med Clin (Barc). 1987;88:125–6.Google Scholar
  181. 181.
    Pewsner D, Bachmann C, Muller U. Allopurinol-induced kidney failure with hepatitis and squamous dermatitis in pre-existing kidney insufficiency. Schweiz Med Wochenschr. 1987;117:139–41.PubMedGoogle Scholar
  182. 182.
    Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31:436–40.PubMedCrossRefGoogle Scholar
  183. 183.
    Foucault V, Pibouin M, Lehry D, et al. Severe drug accidents and allopurinol. Ann Dermatol Venereol. 1988;115:1169–72.PubMedGoogle Scholar
  184. 184.
    McDonald J, Fam AG, Paton T, et al. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J Rheumatol. 1988;15:865–8.PubMedGoogle Scholar
  185. 185.
    Casas E, Puig JG, Mateos FA, et al. The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels. Adv Exp Med Biol. 1989;253A:257–60.PubMedCrossRefGoogle Scholar
  186. 186.
    Coutellier P, Delgrange B. Fatal toxic epidermolysis following administration of allopurinol. Acta Clin Belg. 1989;44:196–8.PubMedGoogle Scholar
  187. 187.
    Gram JT, Gundersen T. Allopurinol hypersensitivity syndrome. Tidsskr Nor Laegeforen. 1989;109:3102–4.PubMedGoogle Scholar
  188. 188.
    Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol. 1989;16:842–4.PubMedGoogle Scholar
  189. 189.
    Stricker BH, Blok AP, Babany G, et al. Fibrin ring granulomas and allopurinol. Gastroenterology. 1989;96:1199–203.PubMedGoogle Scholar
  190. 190.
    Chong RS, Ng HS, Teh LB, et al. Hepatic granulomas: an experience over the last 8 years. Singap Med J. 1990;31:422–6.Google Scholar
  191. 191.
    Collins CE, Thomas DJ, Gumpel JM. Catatonia in the allopurinol hypersensitivity syndrome. BMJ. 1991;302:970.PubMedCrossRefGoogle Scholar
  192. 192.
    Marazuela M, Moreno A, Yebra M, et al. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol. 1991;22:607–13.PubMedCrossRefGoogle Scholar
  193. 193.
    Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum. 1991;34:1329–31.PubMedCrossRefGoogle Scholar
  194. 194.
    Fam AG, Lewtas J, Stein J, et al. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992;93:299–302.PubMedCrossRefGoogle Scholar
  195. 195.
    San Andres Rebollo FJ, Gonzalez Rubio M, Postigo C, et al. Hypersensitivity syndrome caused by allopurinol: report of 2 cases and review of the literature. Rev Clin Esp. 1992;191:426–9.PubMedGoogle Scholar
  196. 196.
    Huang RY, Liu HN, Wong CK. Stevens–Johnson syndrome: a review of 42 cases. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:225–30.Google Scholar
  197. 197.
    Berbegal J, Morera J, Andrada E, et al. Syndrome of allopurinol hypersensitivity. Report of a new case and review of the Spanish literature. Med Clin (Barc). 1994;102:178–80.Google Scholar
  198. 198.
    Braden GL, Warzynski MJ, Golightly M, et al. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70:145–51.PubMedCrossRefGoogle Scholar
  199. 199.
    Fitzgerald DA, Heagerty AH, Stephens M, et al. Follicular toxic pustuloderma associated with allopurinol. Clin Exp Dermatol. 1994;19:243–5.PubMedCrossRefGoogle Scholar
  200. 200.
    Hanger HC, Pillans PI. Death following allopurinol hypersensitivity syndrome. N Z Med J. 1994;107:229.PubMedGoogle Scholar
  201. 201.
    Lee SS, Lin HY, Wang SR, et al. Allopurinol hypersensitivity syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1994;27:140–7.PubMedGoogle Scholar
  202. 202.
    Salinas Martin A, Mendez Abad M, Miguelez M, et al. Hypersensitivity reaction to allopurinol. Aten Primaria. 1994;14:694.PubMedGoogle Scholar
  203. 203.
    Elasy T, Kaminsky D, Tracy M, et al. Allopurinol hypersensitivity syndrome revisited. West J Med. 1995;162:360–1.PubMedGoogle Scholar
  204. 204.
    Gonzalez U, Reyes E, Kershenovich J, et al. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev Invest Clin. 1995;47:409–13.PubMedGoogle Scholar
  205. 205.
    Parra E, Gota R, Gamen A, et al. Granulomatous interstitial nephritis secondary to allopurinol treatment. Clin Nephrol. 1995;43:350.PubMedGoogle Scholar
  206. 206.
    Urban T, Maquarre E, Housset C, et al. Allopurinol hypersensitivity: a possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment. Rev Mal Respir. 1995;12:314–6.PubMedGoogle Scholar
  207. 207.
    Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996;312:173–4.PubMedCrossRefGoogle Scholar
  208. 208.
    Rothwell PM, Grant R. Cerebral vasculitis following allopurinol treatment. Postgrad Med J. 1996;72:119–20.PubMedCrossRefGoogle Scholar
  209. 209.
    Andrade RJ, de la Mata M, Lucena MI, et al. Severe acute hepatitis due to allopurinol in a patient with asymptomatic hyperuricemia and kidney failure. A review of the literature and an analysis of the risk factors. Gastroenterol Hepatol. 1997;20:353–6.PubMedGoogle Scholar
  210. 210.
    Carpenter C. Allopurinol hypersensitivity syndrome. Tenn Med. 1997;90:151–2.PubMedGoogle Scholar
  211. 211.
    Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237–44.PubMedCrossRefGoogle Scholar
  212. 212.
    Choi HK, Merkel PA, Niles JL. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol. 1998;16:743–4.PubMedGoogle Scholar
  213. 213.
    Gillott TJ, Whallett A, Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology (Oxford). 1999;38:85–6.CrossRefGoogle Scholar
  214. 214.
    Grahame R, Simmonds HA, McBride MB, et al. How should we treat tophaceous gout in patients with allopurinol hypersensitivity? Adv Exp Med Biol. 1998;431:19–23.PubMedCrossRefGoogle Scholar
  215. 215.
    Hamanaka H, Mizutani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol. 1998;23:32–4.PubMedCrossRefGoogle Scholar
  216. 216.
    Jappe U, Franke I, Wendekamm U, et al. Allopurinol as an inducer of acute graft-versus-host-like drug reaction. Case report with review of the literature. Hautarzt. 1998;49:126–30.PubMedCrossRefGoogle Scholar
  217. 217.
    Pereira S, Almeida J, Silva AO, et al. Fatal liver necrosis due to allopurinol. Acta Med Port. 1998;11:1141–4.PubMedGoogle Scholar
  218. 218.
    Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med. 1998;52:107–10.PubMedCrossRefGoogle Scholar
  219. 219.
    Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol. 1998;134:1108–12.PubMedCrossRefGoogle Scholar
  220. 220.
    Woss E, Neyer U. Hypersensitivity angiitis following allopurinol therapy. Fortschr Med. 1988;106(730–1):29.Google Scholar
  221. 221.
    Morel D, Guez S, Merville P, et al. Recurrent renal failure associated with hypersensitivity to allopurinol. Nephrol Dial Transpl. 1999;14:780–1.CrossRefGoogle Scholar
  222. 222.
    Tanna SB, Barnes JF, Seth SK. Desensitization to allopurinol in a patient with previous failed desensitization. Ann Pharmacother. 1999;33:1180–3.PubMedCrossRefGoogle Scholar
  223. 223.
    Aoki S, Kotooka N, Yokoyama M, et al. Recurrence of rapidly progressive glomerulonephritis probably associated with two different kinds of drugs. Clin Nephrol. 2000;54:249–51.PubMedGoogle Scholar
  224. 224.
    Brand R, Rohr JB. Toxic epidermal necrolysis in Western Australia. Australas J Dermatol. 2000;41:31–3.PubMedCrossRefGoogle Scholar
  225. 225.
    Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singap Med J. 2000;41:156–60.Google Scholar
  226. 226.
    Arakawa M, Kakuto Y, Ichikawa K, et al. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia. Intern Med. 2001;40:331–5.PubMedCrossRefGoogle Scholar
  227. 227.
    Benito-Leon J, Porta-Etessam J. Guillain–Barre syndrome and allopurinol-induced hypersensitivity. Eur Neurol. 2001;45:186–7.PubMedCrossRefGoogle Scholar
  228. 228.
    Hammer B, Link A, Wagner A, et al. Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome. Dtsch Med Wochenschr. 2001;126:1331–4.PubMedCrossRefGoogle Scholar
  229. 229.
    Rivas Gonzalez P, Calvo Hernandez R, Molinelli Barranco M, et al. Allopurinol hypersensitivity syndrome. Rev Clin Esp. 2001;201:493.PubMedCrossRefGoogle Scholar
  230. 230.
    Anderson BE, Adams DR. Allopurinol hypersensitivity syndrome. J Drugs Dermatol. 2002;1:60–2.PubMedGoogle Scholar
  231. 231.
    Descamps V, Mahe E, Houhou N, et al. Drug-induced hypersensitivity syndrome associated with Epstein–Barr virus infection. Br J Dermatol. 2003;148:1032–4.PubMedCrossRefGoogle Scholar
  232. 232.
    Fine P, Savrinski B, Millodot M. Contact lens management of a case of Stevens–Johnson syndrome: a case report. Optometry. 2003;74:659–64.PubMedGoogle Scholar
  233. 233.
    Masaki T, Fukunaga A, Tohyama M, et al. Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol. 2003;83:128–31.PubMedCrossRefGoogle Scholar
  234. 234.
    Mete N, Yilmaz F, Gulbahar O, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic centrilobular hemorrhagic necrosis. J Investig Allergol Clin Immunol. 2003;13:281–3.PubMedGoogle Scholar
  235. 235.
    Dia D, Ba-Fall K, Bouldouyre M, et al. DRESS syndrome to allopurinol: a case in Dakar. Dakar Med. 2004;49:114–5.PubMedGoogle Scholar
  236. 236.
    Marrakchi C, Kanoun F, Kilani B, et al. Allopurinol induced DRESS syndrome. Rev Med Interne. 2004;25:252–4.PubMedCrossRefGoogle Scholar
  237. 237.
    Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann Pharmacother. 2005;39:1552–6.PubMedCrossRefGoogle Scholar
  238. 238.
    Chen IH, Kuo MC, Hwang SJ, et al. Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J Med Sci. 2005;21:228–32.PubMedCrossRefGoogle Scholar
  239. 239.
    Choi SH, Yang SH, Song YB, et al. A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol. Korean J Hepatol. 2005;11:80–5.PubMedGoogle Scholar
  240. 240.
    Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331:623–4.PubMedCrossRefGoogle Scholar
  241. 241.
    Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134–9.PubMedCrossRefGoogle Scholar
  242. 242.
    Kakeda M, Tohyama M, Iwasaki J, et al. A case of histopathologically typical toxic epidermal necrolysis despite no visible blisters or erosive lesions. J Dermatol. 2005;32:654–60.PubMedGoogle Scholar
  243. 243.
    Saxena R, Loghmanee F. Fatal drug reaction due to allopurinol therapy in a 72-year-old man. Arch Pathol Lab Med. 2005;129:e183–4.PubMedGoogle Scholar
  244. 244.
    Almirall J, Orellana R, Martinez Ocana JC, et al. Allopurinol-induced chronic granulomatous interstitial nephritis. Nefrologia. 2006;26:741–4.PubMedGoogle Scholar
  245. 245.
    Kokunai A, Azusawa H, Murota H, et al. Hypersensitivity reactions to multiple drugs during the course of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Arerugi. 2006;55:662–6.PubMedGoogle Scholar
  246. 246.
    Rodevand E, Sletvold O, Kvande KT. Side effects off allopurinol. Tidsskr Nor Laegeforen. 2004;124:2618–9.PubMedGoogle Scholar
  247. 247.
    Dainichi T, Uchi H, Moroi Y, et al. Stevens–Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215:86–8.PubMedCrossRefGoogle Scholar
  248. 248.
    Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934–40.PubMedCrossRefGoogle Scholar
  249. 249.
    Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:1044–9.PubMedCrossRefGoogle Scholar
  250. 250.
    Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523–6.PubMedCrossRefGoogle Scholar
  251. 251.
    Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singap Med J. 2008;49:384–7.Google Scholar
  252. 252.
    Shalom R, Rimbroth S, Rozenman D, et al. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30:327–9.PubMedCrossRefGoogle Scholar
  253. 253.
    Suzuki HI, Asai T, Tamaki Z, et al. Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia. Haematologica. 2008;93:469–70.PubMedCrossRefGoogle Scholar
  254. 254.
    Yoon JY, Min SY, Park JY, et al. A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J Hepatol. 2008;14:97–101.PubMedCrossRefGoogle Scholar
  255. 255.
    Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145:67–72.PubMedCrossRefGoogle Scholar
  256. 256.
    Gyotoku E, Iwamoto T, Ochi M. A fatal case of drug-induced hypersensitivity syndrome due to allopurinol. Arerugi. 2009;58:560–6.PubMedGoogle Scholar
  257. 257.
    Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens–Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29:633–8.PubMedCrossRefGoogle Scholar
  258. 258.
    Hsieh HJ, Chan AL, Lin SJ. Stevens–Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy. 2009;55:197–9.PubMedCrossRefGoogle Scholar
  259. 259.
    Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51–6.PubMedCrossRefGoogle Scholar
  260. 260.
    Sackesen C, Dut R, Gucer S, et al. Allopurinol-induced DRESS syndrome in a 13-year-old girl. J Investig Allergol Clin Immunol. 2009;19:65–7.PubMedGoogle Scholar
  261. 261.
    Dewan AK, Quinonez RA. Allopurinol-induced DRESS syndrome in an adolescent patient. Pediatr Dermatol. 2010;27:270–3.PubMedCrossRefGoogle Scholar
  262. 262.
    Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010;49:834–41.PubMedGoogle Scholar
  263. 263.
    Fathallah N, Ben Salem C, Slim R, et al. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities. J Clin Rheumatol. 2010;16:170–1.PubMedCrossRefGoogle Scholar
  264. 264.
    Hamaguchi Y, Fujimoto M, Enokido Y, et al. Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol. Int J Dermatol. 2010;49:700–4.PubMedCrossRefGoogle Scholar
  265. 265.
    Santiago F, Goncalo M, Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat. 2010;62:47–53.CrossRefGoogle Scholar
  266. 266.
    Ventura F, Fracasso T, Leoncini A, et al. Death caused by toxic epidermal necrolysis (Lyell syndrome). J Forensic Sci. 2010;55:839–41.PubMedCrossRefGoogle Scholar
  267. 267.
    Yang DC, Chang CM. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence. J Am Geriatr Soc. 2010;58:2043–4.PubMedCrossRefGoogle Scholar
  268. 268.
    Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125:1126 e7–34 e7.CrossRefGoogle Scholar
  269. 269.
    Sekine A, Saito T, Ito S, et al. Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome. Respir Investig. 2012;50:70–5.PubMedCrossRefGoogle Scholar
  270. 270.
    Agnes K, Anna L, Anita V, et al. Allopurinol-induced hypersensitivity syndrome. Orvosi Hetilap. 2012;153:586–91.CrossRefGoogle Scholar
  271. 271.
    Cao ZH, Wei ZY, Zhu QY, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13:1193–201.PubMedCrossRefGoogle Scholar
  272. 272.
    Comparin C, Hans Filho G, Takita LC, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87:477–81.PubMedCrossRefGoogle Scholar
  273. 273.
    Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012;6:84.PubMedCrossRefGoogle Scholar
  274. 274.
    Biagioni E, Busani S, Rinaldi L, et al. Acute renal failure and liver necrosis associated to allopurinol therapy. Anaesth Intensive Care. 2012;40:190–1.PubMedGoogle Scholar
  275. 275.
    Botelho LF, Higashi VS, Padilha MH, et al. DRESS: clinicopathological features of 10 cases from an University Hospital in Sao Paulo. An Bras Dermatol. 2012;87:703–7.PubMedCrossRefGoogle Scholar
  276. 276.
    Chiu ML, Hu M, Ng MH, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167:44–9.PubMedCrossRefGoogle Scholar
  277. 277.
    Gordon K, Miteva M, Torchia D, et al. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis. Cutan Ocul Toxicol. 2012;31:338–40.PubMedCrossRefGoogle Scholar
  278. 278.
    Huang YC, Shih PY, Chin SY, et al. Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. J Dermatol. 2012;39:1077–8.PubMedCrossRefGoogle Scholar
  279. 279.
    Lee MH, Stocker SL, Anderson J, et al. Initiating allopurinol therapy: do we need to know the patient’s human leucocyte antigen status? Intern Med J. 2012;42:411–6.PubMedCrossRefGoogle Scholar
  280. 280.
    Martinez-Aranguren R, Gamboa PM, Garcia-Lirio E, et al. In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Ann Allergy Asthma Immunol. 2012;108:280–1.PubMedCrossRefGoogle Scholar
  281. 281.
    Yaylaci S, Demir MV, Temiz T, et al. Allopurinol-induced DRESS syndrome. Indian J Pharmacol. 2012;44:412–4.PubMedCrossRefGoogle Scholar
  282. 282.
    Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, et al. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol. 2012;92:200–5.PubMedCrossRefGoogle Scholar
  283. 283.
    Onuma H, Tohyama M, Imagawa A, et al. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277–81.PubMedCrossRefGoogle Scholar
  284. 284.
    Laguna C, Martin B, Torrijos A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Actas Dermo-Sifiliograficas. 2006;97:177–85.PubMedCrossRefGoogle Scholar
  285. 285.
    Raymond JZ, Goldman HM. An unusual cutaneous reaction secondary to allopurinol. Cutis. 1988;41:323–6.PubMedGoogle Scholar
  286. 286.
    Fonseka MM, Sathischandra H, Jayamanne SF, et al. Successful desensitisation of allopurinol-induced erythema multiforme. Ceylon Med J. 1999;44:190–1.PubMedGoogle Scholar
  287. 287.
    Edwards R, Ridder M. Stevens–Johnson syndrome: a multisystem case. Dimens Crit Care Nurs. 1985;4:335–48.PubMedCrossRefGoogle Scholar
  288. 288.
    Teo L, Tay YK, Liu TT, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singap Med J. 2009;50:29–33.Google Scholar
  289. 289.
    Turki H, Walha N, Boudaya S, et al. Le syndrome de Lyell (nécrolyse épidermique toxique). Étude de 8 cas. Sem Hôp Paris. 1998;74:953–8.Google Scholar
  290. 290.
    Gil Gonzalez I, Gimenez Garcia RM, Diez Gonzalez G, et al. Toxic epidermal necrolysis caused by allopurinol. Anales de Medicina Interna. 1988;5:649.Google Scholar
  291. 291.
    Quintas S, Do Carmo G, Gama R, et al. Lyell’s syndrome in a patient with AIDS. Acta Medica Portuguesa. 1997;10:509–16.PubMedGoogle Scholar
  292. 292.
    Cid Conde L, Novoa Fernandez E, Padron Rodriguez B. Toxic epidermal necrolysis (Lyell’s syndrome) secondary to alopurinol. Farmacia Hospitalaria. 2009;33:229–30.PubMedCrossRefGoogle Scholar
  293. 293.
    Knezevic A, Frkovic A, Francetic I, et al. Toxic epidermal necrolysis (Lyell’s syndrome) caused by allopurinol. Lijecnicki Vjesnik. 1987;109:272–4.PubMedGoogle Scholar
  294. 294.
    Dicle Ö, Yilmaz E, Alpsoy E. Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective evaluation. Türkderm Deri Hastaliklari ve Frengi Arsivi. 2009;43:15–20.Google Scholar
  295. 295.
    Assaad D, From L, Ricciatti D, et al. Toxic epidermal necrolysis in Stevens–Johnson syndrome. Can Med Assoc J. 1978;118:154–6.PubMedGoogle Scholar
  296. 296.
    Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605–8.PubMedCrossRefGoogle Scholar
  297. 297.
    Gambert SR. Medication-induced Stevens–Johnson syndrome in elders. Clin Geriatr. 2012;20:8.Google Scholar
  298. 298.
    Stenton SB, Dalen D, Wilbur K. Myocardial infarction associated with intravenous immune globulin. Ann Pharmacother. 2005;39:2114–8.PubMedCrossRefGoogle Scholar
  299. 299.
    Bennett TO, Sugar J, Sahgal S. Ocular manifestations of toxic epidermal necrolysis associated with allopurinol use. Arch Ophthalmol. 1977;95:1362–4.PubMedCrossRefGoogle Scholar
  300. 300.
    Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens–Johnson syndrome treated with corticosteroids. Allergy Proc. 1995;16:151–5.PubMedCrossRefGoogle Scholar
  301. 301.
    Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218–21.PubMedCrossRefGoogle Scholar
  302. 302.
    Tan SK, Tay YK. Profile and pattern of Stevens–Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92:62–6.PubMedCrossRefGoogle Scholar
  303. 303.
    Patterson R, Cheriyan S, Greenberger PA. Recurrent dermopathy after remission of Stevens–Johnson syndrome secondary to mild dermal trauma. Allergy Proc. 1995;16:115–8.PubMedCrossRefGoogle Scholar
  304. 304.
    Struck MF, Illert T, Schmidt T, et al. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns. 2012;38:562–7.PubMedCrossRefGoogle Scholar
  305. 305.
    Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology. 2008;217:254–9.PubMedCrossRefGoogle Scholar
  306. 306.
    Trautmann A, Klein CE, Kampgen E, et al. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol. 1998;139:1127–8.PubMedCrossRefGoogle Scholar
  307. 307.
    Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil. 1999;20:406–10.PubMedCrossRefGoogle Scholar
  308. 308.
    Moniz P, Casal D, Mavioso C, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a 15-year retrospective study. Acta Med Port. 2011;24:59–70.PubMedGoogle Scholar
  309. 309.
    Ziemer M, Kardaun SH, Liss Y, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575–600.PubMedCrossRefGoogle Scholar
  310. 310.
    Davies P, Ryan DW. Stevens–Johnson syndrome managed in the Clinitron bed. Intensive Care Med. 1983;9:87–9.PubMedCrossRefGoogle Scholar
  311. 311.
    Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704–9.PubMedCrossRefGoogle Scholar
  312. 312.
    Kelso JM, Keating RM. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol. 1996;97:1171–2.PubMedCrossRefGoogle Scholar
  313. 313.
    Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004;209:29–32.PubMedCrossRefGoogle Scholar
  314. 314.
    Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 2005;30:600–2.PubMedCrossRefGoogle Scholar
  315. 315.
    Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns. 2001;27:372–5.PubMedCrossRefGoogle Scholar
  316. 316.
    Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32.PubMedCrossRefGoogle Scholar
  317. 317.
    Fania L, Giannico MI, Fasciani R, et al. Ocular mucous membrane pemphigoid after Lyell syndrome: occasional finding or predisposing event? Ophthalmology. 2012;119:688–93.PubMedCrossRefGoogle Scholar
  318. 318.
    Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs. 1991;14:634–8.PubMedGoogle Scholar
  319. 319.
    Marra LM, Wunderle RC. Oral presentation of toxic epidermal necrolysis. J Oral Maxillofac Surg. 1982;40:59–61.PubMedCrossRefGoogle Scholar
  320. 320.
    Carmona AF, Redondo AD, Pena LO, et al. Toxic epidermal necrolysis treated with cyclosporin A. Med Intensiva. 2011;35:442–5.PubMedCrossRefGoogle Scholar
  321. 321.
    Bashir S, Shah SM, Babar I. Allopurinol induced Stevens–Johnson syndrome: a case report. J Pak Med Assoc. 2000;50:207–9.PubMedGoogle Scholar
  322. 322.
    Boffa MJ, Chalmers RJ. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1994;131:447.PubMedCrossRefGoogle Scholar
  323. 323.
    Correia O, Chosidow O, Saiag P, et al. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology. 1993;186:32–7.PubMedCrossRefGoogle Scholar
  324. 324.
    Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum. 1966;9:414–23.PubMedCrossRefGoogle Scholar
  325. 325.
    Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol. 1987;123:1166–70.PubMedCrossRefGoogle Scholar
  326. 326.
    Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8:341–6.PubMedCrossRefGoogle Scholar
  327. 327.
    Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617–22.PubMedCrossRefGoogle Scholar
  328. 328.
    Lee HJ, Kim HS, Park YM, et al. Fixed drug eruption due to allopurinol: positive oral provocation. Ann Dermatol. 2011;23:S402–3.PubMedCrossRefGoogle Scholar
  329. 329.
    Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99–107.PubMedCrossRefGoogle Scholar
  330. 330.
    Lun K, Harley W. Allopurinol-induced pustular eruption: an unusually mild case. Australas J Dermatol. 2002;43:140–3.PubMedCrossRefGoogle Scholar
  331. 331.
    Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci. 2005;329:95–8.PubMedCrossRefGoogle Scholar
  332. 332.
    Ooi CG, Walker P, Sidhu SK, et al. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol. 2006;47:270–3.PubMedCrossRefGoogle Scholar
  333. 333.
    Stratigos JD, Bartsokas SK, Capetanakis J. Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. Br J Dermatol. 1972;86:564–7.PubMedCrossRefGoogle Scholar
  334. 334.
    Thomas J. Dermatologic complications of allopurinol treatment of gout. Rein et Foie. 1969;12:129–33.Google Scholar
  335. 335.
    Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139:39–43.PubMedCrossRefGoogle Scholar
  336. 336.
    Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–3.PubMedCrossRefGoogle Scholar
  337. 337.
    Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond). 2005;19:846–53.CrossRefGoogle Scholar
  338. 338.
    Becker D, Enk A, Brauninger W, et al. Granuloma anulare disseminatum as a rare side effect of allopurinol. Hautarzt. 1995;46:343–5.PubMedCrossRefGoogle Scholar
  339. 339.
    Hara Y, Yoshioka M, Yoshiki R, et al. Increased human herpes virus 6 DNA detected by real-time PCR in the saliva of two patients with drug-induced hypersensitivity syndrome. Eur J Dermatol. 2012;22:418–9.PubMedGoogle Scholar
  340. 340.
    Pasero G, Riccioni N, Rizzo G. Prime esperienze con un inibitore della xantina-ossidasi (4-idrossi-pirazolo-(3,4-d)-pirimidina; allopurino) nel trattamento di soggetti gottosi con grave compromissione della funzione renale. La Settimana medica. 1966;54:63–8.Google Scholar
  341. 341.
    Cusido GVI, Aguilar JL. Exantema fijo medicamentoso inducido por alopurinol. Actas Dermo-Sifiliograficas. 1994;85:755–7.Google Scholar
  342. 342.
    Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23:171–81.PubMedCrossRefGoogle Scholar
  343. 343.
    Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol. 1990;39:419–21.PubMedCrossRefGoogle Scholar
  344. 344.
    Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J. 1991;104:115–7.PubMedGoogle Scholar
  345. 345.
    McClintock AD, Egan AJ, Woods DJ, et al. A survey of allopurinol dosage prescribing. N Z Med J. 1995;108:346–7.PubMedGoogle Scholar
  346. 346.
    Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925–34.PubMedCrossRefGoogle Scholar
  347. 347.
    Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J Qual Clin Pract. 2000;20:42–3.PubMedCrossRefGoogle Scholar
  348. 348.
    Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30:567–72.PubMedCrossRefGoogle Scholar
  349. 349.
    Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.PubMedGoogle Scholar
  350. 350.
    Athisakul S, Wangkaew S, Louthrenoo W. Inappropriate prescription of allopurinol in a teaching hospital. J Med Assoc Thai. 2007;90:889–94.PubMedGoogle Scholar
  351. 351.
    Atzori L, Pinna AL, Mantovani L, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department—Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2012;26:1424–30.PubMedCrossRefGoogle Scholar
  352. 352.
    Jung JW, Kim MH, Song WJ, et al. HLA-B58 does not increase allopurinol hypersensitivity among patients with hematologic malignancy. XXII World Allergy Congress; 2012 (4–8 December 2011); Cancun, Mexico: World Allergy Organization; 2012. p. S98.Google Scholar
  353. 353.
    Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545–9.PubMedCrossRefGoogle Scholar
  354. 354.
    Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892–7.PubMedCrossRefGoogle Scholar
  355. 355.
    Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412–21.PubMedCrossRefGoogle Scholar
  356. 356.
    Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15:863–80.PubMedCrossRefGoogle Scholar
  357. 357.
    Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978;23:598–605.PubMedGoogle Scholar
  358. 358.
    Rodnan GP, Robin JA, Tolchin SF, et al. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA. 1975;231:1143–7.PubMedCrossRefGoogle Scholar
  359. 359.
    Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445–9.PubMedCrossRefGoogle Scholar
  360. 360.
    Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008;14:6–11.PubMedCrossRefGoogle Scholar
  361. 361.
    Stamp LK, Barclay ML, O’Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90:392–8.PubMedCrossRefGoogle Scholar
  362. 362.
    Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937–43.PubMedCrossRefGoogle Scholar
  363. 363.
    Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust. 1989;151:531–2 535–7.PubMedGoogle Scholar
  364. 364.
    Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44:1038–42.CrossRefGoogle Scholar
  365. 365.
    Hall AP, Barry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med. 1967;42:27–37.PubMedCrossRefGoogle Scholar
  366. 366.
    Rosenfeld JB. Effect of allopurinol administration on serum GFR in normotensive and hypertensive hyperuricemia subjects. Adv Exp Med Biol. 1974;41B:581–96.CrossRefGoogle Scholar
  367. 367.
    Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74–82.PubMedCrossRefGoogle Scholar
  368. 368.
    Yu TF, Berger L, Dorph DJ, et al. Renal function in gout. V. Factors influencing the renal hemodynamics. Am J Med. 1979;67:766–71.PubMedCrossRefGoogle Scholar
  369. 369.
    McGill NW. Gout and other crystal arthropathies. Med J Aust. 1997;166:33–8.PubMedGoogle Scholar
  370. 370.
    Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2:556–62.PubMedCrossRefGoogle Scholar
  371. 371.
    Pater C. Hyperuricemia and hypertension: a causal relationship ignored for all too long. Curr Hypertens Rev. 2011;7:41–53.CrossRefGoogle Scholar
  372. 372.
    Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.PubMedCrossRefGoogle Scholar
  373. 373.
    Johnson RJ, Feig DI, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18–20.PubMedCrossRefGoogle Scholar
  374. 374.
    Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16:1909–19.PubMedCrossRefGoogle Scholar
  375. 375.
    Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072–8.PubMedCrossRefGoogle Scholar
  376. 376.
    Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl 5):S13–6.PubMedCrossRefGoogle Scholar
  377. 377.
    Gaffo AL, Saag KG. Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet? Am J Cardiovasc Drugs. 2012;12:1–6.PubMedCrossRefGoogle Scholar
  378. 378.
    See LC, Kuo CF, Chuang FH, et al. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol. 2011;30:323–30.PubMedCrossRefGoogle Scholar
  379. 379.
    Goncalves JP, Oliveira A, Severo M, et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41:450–7.PubMedCrossRefGoogle Scholar
  380. 380.
    Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37:883–9.PubMedCrossRefGoogle Scholar
  381. 381.
    Avram Z, Krishnan E. Hyperuricaemia: where nephrology meets rheumatology. Rheumatology. 2008;47:960–4.PubMedCrossRefGoogle Scholar
  382. 382.
    Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.PubMedCrossRefGoogle Scholar
  383. 383.
    Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104–9.PubMedGoogle Scholar
  384. 384.
    Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179–92.PubMedCrossRefGoogle Scholar
  385. 385.
    Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35:498–501.PubMedGoogle Scholar
  386. 386.
    Kitts A, Feolo M, Helmberg W. Allele and haplotype frequencies. dbMHC anthropology search results (HLA-B*58:01:01). National Center for Biotechnology Information (NCBI). http://www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi. Accessed 14 Dec 2012.
  387. 387.
    Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179:32–3.PubMedCrossRefGoogle Scholar
  388. 388.
    Cristallo AF, Schroeder J, Citterio A, et al. A study of HLA class I and class II 4-digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011;38:303–9.PubMedCrossRefGoogle Scholar
  389. 389.
    Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21:303–7.PubMedCrossRefGoogle Scholar
  390. 390.
    Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127:S60–6.PubMedCrossRefGoogle Scholar
  391. 391.
    Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.PubMedCrossRefGoogle Scholar
  392. 392.
    Somkrua R, Chaiyakunapruk N, Tassaneeyakul W. What cost of HLA-B*5801 genotyping would be cost-effective for the prevention of allopurinol-induced Stevens–Johnson syndrome/Toxic Epidermal Necrolysis in Thailand: analyses using a decision-analytic model. Value Health. 2010;13:A564–5.CrossRefGoogle Scholar
  393. 393.
    Yeo SI. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region. Int J Rheum Dis. 2013.Google Scholar
  394. 394.
    Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–6.PubMedGoogle Scholar
  395. 395.
    Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582–7.PubMedGoogle Scholar
  396. 396.
    Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–9.PubMedCrossRefGoogle Scholar
  397. 397.
    Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.PubMedCrossRefGoogle Scholar
  398. 398.
    Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305–9.PubMedCrossRefGoogle Scholar
  399. 399.
    Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004;10:308–14.PubMedCrossRefGoogle Scholar
  400. 400.
    Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–63.PubMedCrossRefGoogle Scholar
  401. 401.
    Fuldeore MJ, Riedel AA, Zarotsky V, et al. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36.PubMedCrossRefGoogle Scholar
  402. 402.
    Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(679–87):e1.Google Scholar
  403. 403.
    Sharpe CR. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can Med Assoc J. 1984;131:563–7.PubMedGoogle Scholar
  404. 404.
    Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004–7.PubMedCrossRefGoogle Scholar
  405. 405.
    Emmerson BT. The management of gout. N Engl J Med. 1996;334:445–51.PubMedCrossRefGoogle Scholar
  406. 406.
    Tikly M, Bellingan A, Lincoln D, et al. Risk factors for gout: a hospital-based study in urban black South Africans. Rev Rhum Engl Ed. 1998;65:225–31.PubMedGoogle Scholar
  407. 407.
    McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14:445–60.PubMedCrossRefGoogle Scholar
  408. 408.
    Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350–5.PubMedGoogle Scholar
  409. 409.
    Mandell BF. Hyperuricemia and gout: a reign of complacency. Cleve Clin J Med. 2002;69:589–90 92–3.PubMedCrossRefGoogle Scholar
  410. 410.
    Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.PubMedCrossRefGoogle Scholar
  411. 411.
    Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083–4.PubMedCrossRefGoogle Scholar
  412. 412.
    Pritchett JC, Nanau RM, Neuman MG. The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatol. 2012;2012:723062.PubMedGoogle Scholar
  413. 413.
    Shiohara T, Kano Y, Takahashi R, et al. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy. 2012;97:122–38.PubMedCrossRefGoogle Scholar
  414. 414.
    Criado PR, Criado RF, Avancini Jde M, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435–49.PubMedCrossRefGoogle Scholar
  415. 415.
    Hirahara K, Kano Y, Mitsuyama Y, et al. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. Clin Exp Dermatol. 2010;35:863–8.PubMedCrossRefGoogle Scholar
  416. 416.
    Mockenhaupt M. Allopurinol is the most frequent cause of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Dermatol. 2012;7:213–5.CrossRefGoogle Scholar
  417. 417.
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.PubMedCrossRefGoogle Scholar
  418. 418.
    de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.PubMedGoogle Scholar
  419. 419.
    Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575–81.PubMedGoogle Scholar
  420. 420.
    Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609–13.PubMedCrossRefGoogle Scholar
  421. 421.
    Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396–402.PubMedCrossRefGoogle Scholar
  422. 422.
    Bull PW, Scott JT. Intermittent control of hyperuricaemia in the treatment of gout. Adv Exp Med Biol. 1989;253A:251–5.PubMedCrossRefGoogle Scholar
  423. 423.
    Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435–42 quiz S65–8.PubMedGoogle Scholar
  424. 424.
    Harrold LR, Mazor KM, Velten S, et al. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263–71.PubMedCrossRefGoogle Scholar
  425. 425.
    Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490–5.PubMedCrossRefGoogle Scholar
  426. 426.
    Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59:809–20.PubMedCrossRefGoogle Scholar
  427. 427.
    Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62:1439–44.PubMedCrossRefGoogle Scholar
  428. 428.
    Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol. 2007;7:299–303.PubMedGoogle Scholar
  429. 429.
    Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10:291–6.PubMedCrossRefGoogle Scholar
  430. 430.
    Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152:968–74.PubMedCrossRefGoogle Scholar
  431. 431.
    Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions: a 20-year review. Contact Dermat. 2011;65:195–201.CrossRefGoogle Scholar
  432. 432.
    Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–16.PubMedCrossRefGoogle Scholar
  433. 433.
    Waton J, Trechot P, Loss-Ayav C, et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol. 2009;160:786–94.PubMedCrossRefGoogle Scholar
  434. 434.
    Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions—new concepts. Clin Exp Allergy. 2007;37:989–99.PubMedCrossRefGoogle Scholar
  435. 435.
    Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin N Am. 2010;94:711–25 x.PubMedCrossRefGoogle Scholar
  436. 436.
    Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken). 2012.Google Scholar
  437. 437.
    Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2012.Google Scholar
  438. 438.
    Riedel MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781–91.Google Scholar
  439. 439.
    Rieder MJ. Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Expert Opin Drug Saf. 2009;8:331–43.PubMedCrossRefGoogle Scholar
  440. 440.
    Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.PubMedCrossRefGoogle Scholar
  441. 441.
    Worswick S, Cotliar J. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207–18.PubMedCrossRefGoogle Scholar
  442. 442.
    Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens–Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009;2:51–5.PubMedGoogle Scholar
  443. 443.
    Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–6.PubMedCrossRefGoogle Scholar
  444. 444.
    Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81–8.PubMedCrossRefGoogle Scholar
  445. 445.
    Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246–55.PubMedCrossRefGoogle Scholar
  446. 446.
    Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol. 2006;45:1117–8.PubMedCrossRefGoogle Scholar
  447. 447.
    Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens–Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112:1430–6.PubMedCrossRefGoogle Scholar
  448. 448.
    Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847–51.PubMedCrossRefGoogle Scholar
  449. 449.
    Tan AW, Thong BY, Yip LW, et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol. 2005;32:1–6.PubMedGoogle Scholar
  450. 450.
    Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71:398–400.PubMedCrossRefGoogle Scholar
  451. 451.
    Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452–9.PubMedCrossRefGoogle Scholar
  452. 452.
    Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.PubMedCrossRefGoogle Scholar
  453. 453.
    French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6:543–9.PubMedCrossRefGoogle Scholar
  454. 454.
    Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg. 2006;25:91–3.PubMedCrossRefGoogle Scholar
  455. 455.
    Momin SB. Review of intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis. J Clin Aesthet Dermatol. 2009;2:51–8.PubMedGoogle Scholar
  456. 456.
    Ferguson JC, Carr RT, Chang EW, et al. Evaluation of endotracheal tube safety for CO2 laser resurfacing. Laryngoscope. 2002;112:1239–42.PubMedCrossRefGoogle Scholar
  457. 457.
    Aronson JK. Anecdotes as evidence. BMJ. 2003;326:1346.PubMedCrossRefGoogle Scholar
  458. 458.
    Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003;37:1774–8.PubMedCrossRefGoogle Scholar
  459. 459.
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.PubMedCrossRefGoogle Scholar
  460. 460.
    Loke YK, Price D, Derry S, et al. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. BMJ. 2006;332:335–9.PubMedCrossRefGoogle Scholar
  461. 461.
    Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33:765–73.PubMedCrossRefGoogle Scholar
  462. 462.
    Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16:581–7.PubMedCrossRefGoogle Scholar
  463. 463.
    Longmore JM, Wilkinson IB, Rajagopalan SR. Oxford handbook of clinical medicine. 6th ed. New York: Oxford University Press; 2004.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Sheena N. Ramasamy
    • 1
    • 2
  • Cameron S. Korb-Wells
    • 1
    • 2
  • Diluk R. W. Kannangara
    • 1
    • 2
  • Myles W. H. Smith
    • 1
    • 2
  • Nan Wang
    • 1
    • 2
  • Darren M. Roberts
    • 1
    • 2
  • Garry G. Graham
    • 1
    • 2
  • Kenneth M. Williams
    • 1
    • 2
  • Richard O. Day
    • 1
    • 2
  1. 1.Department of Clinical Pharmacology and ToxicologySt Vincent’s HospitalDarlinghurstAustralia
  2. 2.School of Medical SciencesUniversity of New South WalesSydneyAustralia

Personalised recommendations